ARCHIVES

NSABP Accrual Slow, But Auditing Called “Impressive”

This article is from The Cancer Letter archive.

Vol. 21 No. 03 | January 20, 1995

Download PDF Visit The Full Archive

Related Articles

Litton Sells Clinical Labs, Planning to Join Recompetition For FCRF Contracts

July 12, 1985

NCI-Approved Clinical Trials

September 28, 2001

CCOP Review Competed, Enough Good Applications In Funding Range To Get Viable Program Started

February 18, 1983

Long-Term Estrogen Use May Increase Ovarian Cancer Risk

April 27, 2001

News Analysis: Generic Drug Industry’s Efforts to Eliminate Shortages Raises Antitrust Law Questions

April 27, 2012

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

October 28, 2011